| What it is | Experimental long‑acting antibody therapy SPY001 being tested in patients with moderate to severe ulcerative colitis | Experimental long‑acting antibody therapy SPY002 being tested in similar patient group | Experimental long‑acting antibody therapy SPY003 being tested in similar patient group | Placebo control given alongside experimental antibodies for comparison | Biologics or JAK inhibitors are guideline‑recommended advanced therapies for moderate to severe ulcerative colitis |
|---|
| Role in trial | One of multiple experimental antibody regimens evaluated | Another experimental antibody regimen evaluated | Another experimental antibody regimen evaluated | Control group receiving placebo | Represents treatments typically used in practice today as a benchmark |
|---|
| Purpose | To evaluate whether SPY001 induces histologic and clinical remission in UC | To evaluate whether SPY002 induces histologic and clinical remission in UC | To evaluate whether SPY003 induces histologic and clinical remission in UC | To provide a comparison baseline for assessing investigational agents | Used in clinical practice to induce and maintain remission in moderate to severe UC |
|---|
| Administration | Administered as long‑acting antibody regimen according to protocol | Administered as long‑acting antibody regimen according to protocol | Administered as long‑acting antibody regimen according to protocol | Placebo injection or infusion matching experimental schedule | Includes intravenous or subcutaneous biologics and oral JAK inhibitors as per guidelines |
|---|
| Evidence status | Efficacy under investigation; no results posted yet | Efficacy under investigation; no results posted yet | Efficacy under investigation; no results posted yet | Placeholder baseline; no efficacy itself | Advanced therapies have established efficacy in inducing and maintaining remission in moderate to severe UC |
|---|
| Important risks | Safety profile not yet established | Safety profile not yet established | Safety profile not yet established | No treatment‑related safety risk beyond placebo administration | Advanced therapies have known risks of infections, injection‑site reactions, and laboratory abnormalities |
|---|
| Important limitations | Multiple experimental arms increase complexity; results not yet available | Similar complexity due to multiple study arms and dosing regimens | Same as other experimental arms | Placebo may not reflect current treatment expectations | Guideline‑recommended therapies may differ in administration method, onset time, and side effects compared to investigational antibodies |
|---|
